* On its third quarter fiscal 2011 unaudited financial results, AERL posted revenue of $74.4 million, a 161% increase compared to the same period the prior year.

************************

** CVV reported results for the three months ended September 30, 2011, posting record revenue of $8,844,000, an increase of 18% sequentially and up 119% year over year.

************************

** NGSX reported that the FDA has accepted for review its supplemental new drug application for Qutenza 8% Patch for the management of neuropathic pain associated with HIV-associated peripheral neuropathy, the most common neurological complication of HIV infection.